News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

New oral tyrosine kinase 2 inhibitor shows promise against moderate-to-severe plaque psoriasis
23 Apr 2022
PF-06826647, a novel tyrosine kinase 2 inhibitor in development, outperforms placebo at reducing disease severity in patient with moderate-to-severe plaque psoriasis, reveals a new trial.
23 Apr 2022

Circulating antioxidants play no protective role in breast, ovarian cancers
23 Apr 2022
Genetically predicted circulating antioxidants do not appear to have a protective effect on the risk of breast cancer, ovarian cancer, or their histotypes, according to the results of a two-sample Mendelian randomization study.
23 Apr 2022

Furmonertinib emerges as potential first-line option for EGFRm NSCLC
22 Apr 2022
byRoshini Claire Anthony
Treatment-naïve patients with locally advanced or metastatic EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) experience improved progression-free survival (PFS) when treated with furmonertinib compared with gefitinib, according to results of the phase III FURLONG study.
22 Apr 2022






